All News

Pharmacists play a vital role in managing multiple sclerosis treatments, enhancing patient care through clinical trials and personalized therapy options.

Zavabresib receives orphan drug designation for myelofibrosis, offering hope for patients unresponsive to current treatments and enhancing therapeutic options.

Pharmacists should know about migraine treatments, such as lasmiditan, to effectively treat and educate patients with acute migraine.

The authors suggested that future research investigate emerging blood-based biomarkers and explore temporal associations between sleep duration and Alzheimer disease biomarker changes.

Research reveals that asthma patients with depression show elevated BDNF levels, suggesting unique biological links between asthma severity and depressive symptoms.

On Chen and Tahmid Rahman join Pharmacy Focus to discuss the world's first commercial administration of plozasiran at Stony Brook Medicine.

RegeneCyte's HPC therapy shows promise in treating long COVID symptoms, with 85% of patients reporting fatigue relief.

The FDA prioritizes centanafadine's review for ADHD treatment, offering a novel, once-daily oral option for diverse patient needs.

Processed plant-based foods like breads and cereal can reduce the risk of diabetes and heart failure when they replace ultra-processed meats or sugary beverages.

Research shows weight regain after discontinuation of GLP-1 or GLP-1/GIP agonists is a significant risk.

Discover groundbreaking FDA-approved treatments, including at-home depression therapy, new biosimilars, and culturally relevant pain relief options.

Atebimetinib shows promise in enhancing pancreatic cancer treatment, achieving a 64% survival rate and improving patient quality of life.

Shawn Riser Taylor, PharmD, CPP, CDCES, reflects on a research career shaped by a commitment to patient-driven inquiry and a passion for collaborative, learner-engaged projects.

Multidisciplinary coordination and streamlined workflows enabled rapid patient access to plozasiran after FDA approval at Stony Brook University Hospital.

CMS announces the selection of 15 high-cost drugs for Medicare price negotiations, aiming to reduce prescription costs for older adults and taxpayers.

Key updates include treatment thresholds, dietary recommendations, and management strategies.

Pharmacists play a vital role in identifying and managing primary immunodeficiency diseases, enhancing patient outcomes through immunoglobulin therapy and education.

David Shusterman, MD, reveals how reducing alcohol enhances GLP-1 therapy, improving insulin regulation, kidney health, and overall metabolic outcomes.

Dextromethorphan offers unique mechanisms and potential benefits over traditional antidepressants.

FDA approves a new quadruplet therapy for newly diagnosed multiple myeloma, enhancing treatment options for patients ineligible for stem cell transplant.

Pharmacists play a vital role in supporting multiple sclerosis patients by addressing medication challenges, educating on treatments, and navigating insurance hurdles.

Experts say SMS-based engagement tools can help pharmacists improve medication adherence and reduce hospital readmissions by addressing common patient barriers such as forgetfulness and cost.

Updated guidelines on PA call for expanded screening, treatment, and monitoring, creating opportunities for pharmacists to screen all patients with hypertension.

Explore how pharmacists enhance access to care for multiple sclerosis patients, tackling barriers in diagnosis, treatment, and patient education.

Cardiotoxic signals released from the kidneys may drive cardiovascular risk in patients with chronic kidney disease, opening the door to earlier detection and targeted treatment.

GLP-1 receptor agonist effectiveness and tolerability can be significantly improved through targeted pharmacist counseling on alcohol reduction.